On March 9, 2026, Hims & Hers Health announced a strategic partnership with pharmaceutical giant Novo Nordisk that will bring branded Ozempic (semaglutide) injections and Wegovy pills and injections onto the Hims & Hers telehealth platform. Concurrent with the announcement, Novo Nordisk dropped its patent infringement lawsuit against Hims & Hers — a suit filed in February 2026 over the company's sale and marketing of compounded GLP-1 weight loss drugs.

Why It Matters

While the Novo Nordisk deal is primarily about GLP-1 weight loss drugs, it has profound implications for Hims' sexual health business. The company built its brand on destigmatizing ED treatment through telehealth — and that franchise now sits inside a much larger, more legitimate healthcare platform. The stock surge and analyst upgrades signal that Wall Street is finally valuing Hims as a healthcare company rather than a "bro wellness" play, which could open doors for deeper investment in sexual health R&D and expanded product lines.

Under the agreement, Hims will offer access to injectable and oral semaglutide products at the same price as other telehealth platforms, while ceasing to advertise compounded GLP-1 drugs on its platform or in its marketing. Compounded versions will be limited to cases where FDA-approved options don't meet clinical needs. CEO Andrew Dudum framed the pivot as a win: "FDA-approved GLP-1 treatments are now more accessible, with greater affordability."

Wall Street responded with enthusiasm. HIMS stock surged approximately 57% in the week following the announcement — its best week on record. Major firms including Goldman Sachs and JP Morgan upgraded the stock from "Neutral" to "Overweight," with analysts noting that the deal transforms Hims from a scrappy telehealth disruptor into a legitimate pharmaceutical distribution partner.

Warren Templeton of Health2047 called the collaboration a "vital lifeline" for Hims & Hers following mounting regulatory pressure on compounded drugs. The deal effectively ends the company's "compounding era" and positions it as a branded partner to Big Pharma, though its legacy sexual health segments — ED treatments, hair loss, and skincare — continue to provide high-margin stability with new innovations in topical ED treatments.

Sources

Update — 2026-03-15

Initial entry — story first created.

Update — 2026-03-19

Hims & Hers' transformation from telehealth upstart to global healthcare platform accelerated dramatically in the weeks following the Novo Nordisk deal. On February 19, 2026, the company announced a definitive agreement to acquire Eucalyptus, an Australian-based international digital health company, for up to $1.15 billion — by far the largest acquisition in Hims' history. Approximately $240 million will be paid in cash at closing, with the remainder structured as guaranteed deferred payments over 18 months and earnout payments through early 2029. Eucalyptus operates five digital healthcare clinics across Australia, Japan, Germany, Canada, and the UK, including women's weight-loss brand Juniper, men's health platforms Pilot and Compound, and reproductive healthcare brand Kin. Eucalyptus boasts an annual revenue run-rate exceeding $450 million with triple-digit year-over-year growth throughout 2025. CEO Tim Doyle will become SVP of International at Hims.

The deal came just weeks after the FDA issued warning letters to 30 telehealth companies on March 3 over misleading marketing of compounded GLP-1 drugs — the agency's second wave of enforcement since September 2025. While Hims was not named specifically, the crackdown underscored the urgency of the company's pivot toward branded drugs via the Novo Nordisk partnership.

FY 2025 financials paint a company on a tear: revenue hit $2.35 billion (up 59% YoY), and the company posted its second consecutive year of GAAP net income at $128.4 million. Citigroup upgraded HIMS from Sell to Neutral, raising its price target from $13.25 to $24.00, while Deutsche Bank lifted its target from $25.00 to $28.00. However, profit-taking set in by March 12 (HIMS closed down 7.88%), and insider selling continued — COO Michael Chi sold 97,289 shares (~$2.4M) on March 17.

New Sources

Update — 2026-03-22

Hims & Hers continued its breakneck transformation this week. On March 21, the company officially launched Novo Nordisk's Wegovy oral pill on its platform, with CEO Andrew Dudum calling it "the fastest GLP-1 launch in history." The move cements the Novo partnership announced March 9 and marks Hims' definitive pivot from compounded to branded pharmaceuticals.

In a quieter but potentially significant expansion of its men's health portfolio, Hims partnered with Marius Pharmaceuticals to offer KYZATREX — an FDA-approved needle-free oral testosterone replacement therapy shown to restore testosterone levels in up to 96% of men. The partnership extends Hims' sexual health franchise beyond ED into testosterone replacement, a market historically dominated by injections and topical gels.

However, legal headwinds persist. On March 20, shareholder litigation firm Kahn Swick & Foti announced a fiduciary duty investigation into Hims, and shares dropped approximately 7% on March 18 amid continued scrutiny of the company's prior compounded drug practices. The stock remains volatile despite Barclays raising its price target to $29 following the Novo deal.

New Sources

Update — 2026-03-31

The Hims & Hers rollercoaster continued through late March. On March 27, HIMS stock dropped 7% as institutional confidence wavered — JPMorgan slashed its stake from 8.1% to 1.7%, signaling a major exit by one of the company's largest institutional holders. The selloff was compounded by ongoing shareholder litigation from Kahn Swick & Foti probing potential fiduciary duty breaches related to the company's prior compounded drug practices, and by analyst forecasts projecting a 31% shrinkage in Hims' GLP-1 franchise amid growing competition.

The legal headwinds persist despite the March 9 Novo Nordisk reconciliation. While the partnership deal ended the patent lawsuit and gave Hims branded Wegovy and Ozempic distribution rights, questions remain about whether the company's prior compounded drug sales created lasting regulatory liability. The stock remains down significantly from its post-deal high, reflecting market uncertainty about whether the branded pharma pivot can fully offset the revenue lost from high-margin compounded alternatives. The Eucalyptus acquisition (up to $1.15 billion) and KYZATREX testosterone partnership continue to diversify the platform beyond the GLP-1 volatility, but Hims' trajectory in Q2 2026 hinges on how quickly branded drug sales can ramp.

New Sources

Update — 2026-04-08

The Novo Nordisk partnership is now live and delivering results. Hims & Hers officially launched a broad lineup of Novo Nordisk FDA-approved GLP-1 therapies starting at $149, including multiple Wegovy injection and pill formulations. HIMS stock surged 5.96% on April 6 as investors refocused on the growth outlook. A second tailwind arrived from the FDA, which is reportedly moving to ease restrictions on compounded peptides, allowing pharmacies to manufacture over a dozen injectable peptides previously banned — a roughly 4% positive stock catalyst. The combination of branded Novo Nordisk distribution rights, FDA peptide relief, and upcoming Q1 earnings (expected May 4) has shifted sentiment back toward optimism, even as the data breach disclosed April 2 and the Schall Law Firm securities investigation create legal overhang. Revenue guidance remains $2.7–2.9 billion for 2026, with adjusted EBITDA of $300–375 million.

New Sources

Update — 2026-04-18

April 16 regulatory tailwind: On April 16, 2026, two regulatory signals dropped simultaneously and sent Hims & Hers stock up 11% on 74.6 million shares traded (111% above average). First, the FDA announced it is inviting TRT manufacturers to submit data for a new indication covering low libido in men with idiopathic hypogonadism — expanding the potential TRT-eligible patient population significantly and playing directly into Hims' branded oral testosterone (KYZATREX) ambitions. Second, RFK Jr. signaled the FDA may remove 12 peptides from Category 2 compounding restrictions, potentially legalizing the gray-market peptide category that Hims has been navigating since the compounding ban. Bank of America raised its price target from $21 to $25. The dual announcements represent the best regulatory day Hims has had since the Novo Nordisk partnership announcement in March.

April 2 data breach: Hims & Hers separately disclosed that hackers breached its third-party customer support ticketing system via social engineering between February 4–7, 2026, stealing customer names, email addresses, and other personal data from support tickets. Medical records were not accessed. The breach was disclosed via a California AG filing. The number of affected users was not disclosed, and no ransom demand has been confirmed publicly. For a telehealth company built on trust with patients sharing sensitive health and sexual health data, the breach underscores the cybersecurity obligations that come with scale.

New Sources

Update — 2026-04-24

Hims & Hers had two major announcements in quick succession on April 22–23, 2026, and both rewarded shareholders. On April 22, the company launched menopause and perimenopause treatment on its Hers platform — a major expansion into femtech that had been foreshadowed since the Eucalyptus acquisition closed. Estrogen patch kits start at $134/month and the platform will also prescribe progesterone where clinically appropriate. Critically, Hims said it has secured inventory sufficient to serve eligible patients without disruption amid a nationwide estrogen patch shortage that industry sources say could last up to three years. Bank of America raised its price target to $30 from $25 the same day, citing the menopause expansion and the April 16 FDA peptide and TRT catalysts.

On April 23, the company expanded its Eli Lilly partnership to offer the full LillyDirect GLP-1 lineup — Zepbound vials, Zepbound KwikPen, and Foundayo — prescribed through Hims clinicians and fulfilled through Lilly's own pharmacy. Shares climbed roughly 7% on the news, building on the Novo Nordisk partnership that ended the patent suit in March. The dual-GLP-1 strategy (Novo Nordisk's Wegovy/Ozempic plus Lilly's Zepbound/Foundayo) effectively makes Hims the single largest telehealth distribution partner for branded GLP-1s in the US.

The immediate risk is competition: Amazon's GLP-1 subscription pricing and Ro's aggressive discounting are both pressuring Hims' market share in the weight-loss franchise, and shareholder litigation (Bronstein, Gewirtz & Grossman announced an investigation on April 23) continues to loom. But the menopause launch diversifies beyond GLP-1s into a high-growth femtech category, and the Eli Lilly deal cements Hims' transformation from compounded-drug disruptor to pharma distribution partner.

New Sources

Update — 2026-04-25

On April 24, 2026, JPMorgan initiated coverage of Hims & Hers with an Overweight rating and a $35 price target — its first formal call on the stock — sending shares up roughly 4% in pre-market trading. Analyst Cory Carpenter framed the Novo Nordisk partnership as a "compelling path" that legitimizes the GLP-1 business and "could mark a turning point" in unwinding the legal and regulatory overhang from the compounded drug era. The thesis: Hims is no longer a compounding-disruptor at risk of FDA action but a multi-platform distributor of branded, generic, and compounded products positioned for a sustainable growth trajectory.

Carpenter's note specifically called out the company's diversification past GLP-1s — menopause care launched April 22, KYZATREX testosterone in the men's health franchise, the FDA's new TRT libido indication pathway opened April 20, and the Eucalyptus international expansion — as the basis for the $35 PT (versus the stock's mid-$25 range entering April). The JPMorgan upgrade follows Bank of America's PT raise to $30 on April 22 and Barclays' $29 PT, indicating broad sell-side recovery from the Q1 selloff.

For Hims' sexual health franchise, the JPMorgan endorsement matters because it formalizes Wall Street's recognition that ED, testosterone, and now menopause are durable revenue legs separate from the volatile GLP-1 business. With the FDA TRT libido indication potentially opening within 12–24 months, KYZATREX gains a labeled-indication advantage. JPMorgan's bull case effectively argues the sexual health vertical, not the weight-loss vertical, is the company's most defensible long-term moat.

New Sources

Update — 2026-05-27

The GLP-1 play was the appetizer — wellness and longevity are the main course. The Washington Post reported on May 24, 2026 that Hims & Hers is pivoting beyond its weight-loss compounder identity toward a broader "wellness and longevity" platform, with peptides — if authorized by the FDA — positioned to become a major product category. The company's 2026 revenue guidance continues to hinge on access to compounded semaglutide, but the Lilly partnership (following the earlier Novo Nordisk Wegovy deal) signals a deliberate repositioning as a technology intermediary connecting patients to branded pharmaceuticals rather than a compounder of generic alternatives.

The financial picture reinforces the pivot's logic: Hims & Hers hit $2.35 billion in revenue in 2025 (up 59% YoY), surpassed 2.5 million subscribers, posted $318 million in adjusted EBITDA, and generated $300 million in operating cash flow. The company raised $402.5 million in convertible senior notes due 2032, providing a substantial capital buffer. Director David B. Wells purchased 48,400 shares at $24.24 on May 26, signaling insider confidence. Truist raised its price target on the stock citing GLP-1 insights.

For the sexual health business that built Hims — ED prescriptions, testosterone, PE treatments — the question is whether the wellness/longevity pivot dilutes focus on the core sexual health vertical or simply provides a bigger platform to cross-sell. With Amazon's One Medical now offering competing GLP-1 access and telehealth ED services, the competitive landscape is intensifying.

New Sources